Diagnosis, treatment, and prognosis of stage IB non-small cell lung cancer with visceral pleural invasion

Abstract

With the increasing implementation of early lung cancer screening and the increasing emphasis on physical examinations, the early-stage lung cancer detection rate continues to rise. Visceral pleural invasion (VPI), which denotes the tumor’s breach of the elastic layer or reaching the surface of the visceral pleura, stands as a pivotal factor that impacts the prognosis of patients with non-small cell lung cancer (NSCLC) and directly influences the pathological staging of early-stage cases. According to the latest 9th edition of the TNM staging system for NSCLC, even when the tumor diameter is less than 3 cm, the final T stage remains T2a if VPI is present. There is considerable controversy within the guidelines regarding treatment options for stage IB NSCLC, especially among patients exhibiting VPI. Moreover, the precise determination of VPI is important in guiding treatment selection and prognostic evaluation in individuals with NSCLC. This article aims to provide a comprehensive review of the current status and advancements in studies pertaining to stage IB NSCLC accompanied by VPI.

Exosomal microRNAs in lung cancer: a narrative review

“…Therefore, early screening and diagnosis are a way to reduce mortality ( 3 ). Research has shown that combining genomics and genetics screening can improve the survival rate for lung cancer patients ( 4 - 6 ). Blood is the easiest source to obtain to acquire information about lung cancer ( 7 ), including circulating DNA and RNA ( 8 ), circulating tumor cells ( 9 ), serum metabolites ( 10 ), and lipids ( 11 ).…”